

PSO-TARGET: a new tool to identify the therapeutic expectations of psoriasis patients treated with biologics

Ziad Reguiai¹, Pierre-Dominique Ghislain², Pierre Moulin³, Emilie Baudier⁴, Corentin Schepkens⁴, Maxime Sintès⁵, Thierry Boyé⁶

¹ Department of Dermatology, Polyclinique Courlancy-Bezannes, Reims, France.

² Cliniques Universitaires Saint-Luc, Brussels, Belgium.

³ Centre de recherche sur les médiations (Crem, UR 3476), Université de Lorraine, Nancy, Grand Est, France.

⁴ LEO Pharma NV/SA, Lier, Belgium.

⁵ LEO Pharma, Courbevoie, France.

⁶ Service de Dermatologie, Hôpital d'Instruction des Armées Ste Anne, Toulon, France.

Corresponding author:

Dr Ziad Reguiai

Polyclinique Reims-Bezannes

89 Rue Victor De Broglie

51430 Bezannes, FRANCE

dr-reguiai@orange.fr

orcid.org/0000-0003-4844-3559

SUPPLEMENTARY TABLES

Table S1. Validity of the PSO-TARGET QoL grid vs DLQI at 12/16 weeks and at 52 weeks.

		At 12/16 weeks	At 52 weeks
True positives	N	129	98
	TP	79 (61.2%)	66 (67.3%)
	IC95%	[52.3 ; 69.7]	[57.1 ; 76.5]%
False positives	N	129	98
	FP	27 (20.9%)	21 (21.4%)
	IC95%	[14.3 ; 29.0]	[13.8 ; 30.9]%
False negatives	N	129	98
	FN	8 (6.2%)	5 (5.1%)
	IC95%	[2.7 ; 11.9]	[1.7 ; 11.5]%
True negatives	N	129	98
	TN	15 (11.6%)	6 (6.1%)
	IC95%	[6.7 ; 18.5]	[2.3 ; 12.9]%

QoL = Quality of life; DLQI = Dermatology life quality index.

Table S2. DLQI and PASI scores at 12/16 weeks and at 52 weeks

		At 12/16 weeks	At 52 weeks
DLQI score (classes)	N	137	112
	Missing data	6	31
	0-1 = no effect at all on patient's life	89 (65.0%)	81 (72.3%)
	02-05 = small effect on patient's life	25 (18.2%)	20 (17.9%)
	06-10 = moderate effect on patient's life	8 (5.8%)	7 (6.3%)
	11-20 = very large effect on patient's life	14 (10.2%)	4 (3.6%)
	21-30 = extremely large effect on patient's life	1 (0.7%)	0
DLQI score	N	137	112
	Missing data	6	31
	0-1	89 (65.0%)	81 (72.3%)
	≥ 2	48 (35.0%)	31 (27.7%)
Relative change from baseline (by class)	N	137	113
	Missing data	0	0
	PASI < 90 (relative change > -90%)	46 (33.6%)	29 (25.7%)
	PASI ≥ 90 (relative change ≤ -90%)	91 (66.4%)	84 (74.3%)
	PASI < 100 (relative change > -100%)	69 (50.4%)	43 (38.1%)
	PASI = 100 (relative change = -100%)	68 (49.6%)	70 (61.9%)

DLQI = Dermatology life quality index; PASI = Psoriasis area severity index.

Table S3. Sensitivity/Specificity of the PSO-TARGET grid at 12/16 weeks and at 52 weeks

		At 12/16 weeks	At 52 weeks
Sensitivity	N	87	71
	Se	79 (90.80%)	66 (92.96%)
	IC95%	[82.68 ; 95.95]%	[84.33 ; 97.67]%
Specificity	N	42	27
	Sp	15 (35.71%)	6 (22.22%)
	IC95%	[21.55 ; 51.97]%	[8.62 ; 42.26]%